Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications

BACKGROUND: Denosumab is an effective treatment for giant cell tumor of the bone (GCTB) but can cause clinically significant adverse effects. Current approved dosing is every 4 weeks after 3 weekly loading doses. We assessed whether alternative, longer dosing intervals are associated with difference...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Cindy Y, Zhao, Lili, Schuetze, Scott M, Chugh, Rashmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Sarcomas
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256029/
https://www.ncbi.nlm.nih.gov/pubmed/35589095
http://dx.doi.org/10.1093/oncolo/oyac066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256029/
https://www.ncbi.nlm.nih.gov/pubmed/35589095
http://dx.doi.org/10.1093/oncolo/oyac066

Ejemplares similares